Trump Strikes Lilly, Novo Deals to Cut GLP-1 Costs and Expand Medicare Coverage

Overview

• Initial oral GLP-1 doses would be offered at about $149 per month for Medicare and Medicaid beneficiaries and via the TrumpRx platform, subject to approvals.
• Prices for currently available injectable GLP-1s used for covered conditions would drop to $245 per month for Medicare and Medicaid patients, with Medicare copays capped at $50.
• The administration says Medicare coverage for obesity treatment will broaden next year, with discounted cash prices starting as soon as January, Medicare pricing by mid-2026, and Medicaid uptake varying by state.
• Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound anchor the agreements, with new oral versions priced at $149 at launch if cleared by regulators.
• Officials caution that what patients pay will vary based on regulatory outcomes, private insurer participation, state Medicaid decisions, dose levels and market competition.